FibroBiologics宣布新型人工胸腺类器官技术概念的初步证明-动脉网

FibroBiologics Announces Preliminary Proof of Concept for Novel Artificial Thymus Organoid Technology

BioSpace 等信源发布 2024-06-25 11:34



可切换为仅中文







HOUSTON, June 25, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc., (Nasdaq: FBLG) ('FibroBiologics'), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced the development of a novel artificial thymus organoid that can restore immune function in a severe combined immunodeficiency (SCID) mouse model..

休斯顿，2024年6月25日（环球通讯社）--FibroBiologics，Inc.（纳斯达克：FBLG）（“FibroBiologics”）是一家临床阶段的生物技术公司，拥有150多项专利，已发布并正在申请中，重点是开发使用成纤维细胞和成纤维细胞衍生材料治疗慢性疾病的疗法和潜在疗法，宣布开发一种新型人工胸腺类器官，可以在严重联合免疫缺陷（SCID）小鼠模型中恢复免疫功能。。

The organoid, composed of fibroblasts and thymus derived cells, is capable of generating mature and diverse T cells, including CD4, CD8, and regulatory T cells, in vitro and in vivo. FibroBiologics intends to develop this technology as a subcutaneous injection of an allogeneic fibroblast-based organoid to restore thymus function lost due to age-related natural thymus involution, and for a rapid restoration of the immune system in patients who have gone through chemotherapy..

由成纤维细胞和胸腺衍生细胞组成的类器官能够在体外和体内产生成熟和多样的T细胞，包括CD4，CD8和调节性T细胞。FibroBiologics打算开发这项技术，作为皮下注射同种异体成纤维细胞为基础的类器官，以恢复由于年龄相关的自然胸腺退化而丧失的胸腺功能，并快速恢复接受化疗的患者的免疫系统。。

'This early research demonstrates the versatility and potential of fibroblasts and fibroblast-derived materials for regenerative medicine and immunotherapy,' said Hamid Khoja, Ph.D., Chief Scientific Officer. 'Immune system dysregulation is the major cause of chronic inflammation, chronic diseases, and age-related immune senescence attributed to higher rates of cancer, autoimmune disorder, infection rate, and reduced response to vaccination in the elderly.

首席科学官哈米德·科哈博士说：“这项早期研究证明了成纤维细胞和成纤维细胞衍生材料在再生医学和免疫治疗中的多功能性和潜力。”免疫系统失调是慢性炎症，慢性疾病和与年龄相关的免疫衰老的主要原因，这归因于癌症，自身免疫性疾病，感染率较高以及老年人对疫苗接种的反应降低。

We look forward to advancing this technology through further research efforts and to offer a new potential treatment for restoring thymus function and enabling a longer and healthier life.'.

我们期待着通过进一步的研究努力推进这项技术，并为恢复胸腺功能和延长健康寿命提供新的潜在治疗方法。”。

'We are very encouraged with the results of our experimental studies in improving human longevity that demonstrate the feasibility of restoring thymus functionality with our artificial thymus organoid technology,' said Pete O’Heeron, Founder and Chief Executive Officer. 'We believe that this technology has the potential to revolutionize the field of immunotherapy and provide a safe and effective alternative to stem cell transplantation.'.

创始人兼首席执行官皮特·奥希伦（PeteO'Heeron）说：“我们在提高人类寿命方面的实验研究结果非常令人鼓舞，这些研究证明了利用我们的人工胸腺类器官技术恢复胸腺功能的可行性。”我们相信这项技术有可能彻底改变免疫治疗领域，并为干细胞移植提供安全有效的替代方案。”。

For more information, please visit FibroBiologics' website or email FibroBiologics at: info@fibrobiologics.com.

有关更多信息，请访问FibroBiologics的网站或发送电子邮件至FibroBiologics：info@fibrobiologics.com.

Cautionary Statement Regarding Forward-Looking Statements

关于前瞻性声明的警示声明

This communication contains 'forward-looking statements' as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements include information concerning the potential and capabilities of fibroblasts and organoids in restoring immune function, generating mature and diverse T cells, revolutionizing the field of immunotherapy and providing a safe and effective alternative to stem cell transplantation, potential treatments being developed, and potential indications.

本通讯包含1995年《私人证券诉讼改革法案》中定义的“前瞻性声明”。前瞻性声明包括有关成纤维细胞和类器官在恢复免疫功能，产生成熟和多样化T细胞，彻底改变免疫治疗领域以及为干细胞移植提供安全有效替代方案，正在开发的潜在治疗方法和潜在指征方面的潜力和能力的信息。

These forward-looking statements are based on FibroBiologics' management's current expectations, estimates, projections and beliefs, as well as a number of assumptions concerning future events. When used in this communication, the words 'estimates,' 'projected,' 'expects,' 'anticipates,' 'forecasts,' 'plans,' 'intends,' 'believes,' 'seeks,' 'may,' 'will,' 'should,' 'future,' 'propose' and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements.

这些前瞻性陈述基于FibroBiologics管理层目前的期望、估计、预测和信念，以及有关未来事件的一些假设。在本通信中使用“估计”、“预计”、“预期”、“预测”、“计划”、“打算”、“相信”、“寻求”、“可能”、“将会”、“应该”、“未来”、“提议”等词语或类似表达（或此类词语或表达的负面版本）的变体，旨在识别前瞻性陈述。

These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside FibroBiologics' management's control, that could cause actual results to differ materially from the results discussed in the forward-looking statements, including those set forth under the caption 'Risk Factors' and elsewhere in FibroBiologics' annual, quarterly and current reports (i.e., Form 10-K, Form 10-Q and Form 8-K) as filed or furnished with the SEC and any subsequent public filings.

这些前瞻性声明并不能保证未来的业绩、条件或结果，涉及许多已知和未知的风险、不确定性、假设和其他重要因素，其中许多因素不在FibroBiologics管理层的控制范围内，可能导致实际结果与前瞻性声明中讨论的结果存在实质性差异，包括标题“风险因素”下以及FibroBiologics提交或提交给SEC的年度、季度和当前报告（即10-K表、10-Q表和8-K表）以及任何后续公开文件中的其他内容。

Copies are available on the SEC's website, www.sec.gov. These risks, uncertainties, assumptions and other important factors inclu.

可在SEC网站www.SEC.gov上获得副本。这些风险、不确定性、假设和其他重要因素包括。

About FibroBiologics

关于纤维生物学

Based in Houston, FibroBiologics is a cell therapy and regenerative medicine company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 150+ US and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, wound healing, reversing organ involution, and cancer.

总部位于休斯顿的FibroBiologics是一家细胞治疗和再生医学公司，开发一系列治疗方法，并利用成纤维细胞和成纤维细胞衍生材料寻求慢性疾病的潜在治疗方法。。

FibroBiologics represents the next generation of medical advancement in cell therapy. For more information, visit www.FibroBiologics.com..

纤维生物学代表了细胞疗法的下一代医学进步。有关更多信息，请访问www。纤维生物制品公司。。

Investor Relations:

投资者关系：

Nic Johnson

尼克·约翰逊

Russo Partners

212-845-4242

fibrobiologicsIR@russopr.com

Media Contact:

媒体联系人：